Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers

Advanced Drug Delivery Reviews

Volumn 81, Issue , 2015, Pages 184-197

  Dai, Xin ^a   Tan, Chalet ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Anti miR; Co delivery; Combination therapy; MicroRNA mimic; Nanocarrier; Small molecule anticancer drug

Indexed keywords

CELL DEATH; DISEASES; DRUG THERAPY; MOLECULES; TUMORS;

ANTI-MIR; ANTICANCER DRUG; CO DELIVERIES; COMBINATION THERAPY; MICRORNAS; NANOCARRIERS;

RNA;

ABC TRANSPORTER; AGENTS AFFECTING NUCLEIC ACID METABOLISM; ANTAGOMIR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARSENIC TRIOXIDE; CARBON NANOPARTICLE; CHITOSAN; CISPLATIN; DENDRIMER; DOXORUBICIN; GEMCITABINE; GRAPHENE; MICRORNA; MICRORNA 155; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 21 INHIBITOR; MICRORNA 29; MICRORNA 34A; NANOCARRIER; NANOPARTICLE; PACLITAXEL; POLY(DIMETHYLAMINOETHYLMETHACRYLATE); POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYMER; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; NANOMATERIAL;

APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MICELLE; NONHUMAN; REVIEW; RNA INTERFERENCE; TUMOR VASCULARIZATION; ANIMAL; DRUG RESISTANCE; GENETICS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; NEOPLASMS;

EID: 84922243829     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.09.010     Document Type: Review

References (201)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15524-15529.
3. Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 2013, 12:847-865.
4. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
5. Pasquinelli A.E. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 2012, 13:271-282.
6. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
7. Musumeci M., Coppola V., Addario A., Patrizii M., Maugeri-Sacca M., Memeo L., Colarossi C., Francescangeli F., Biffoni M., Collura D., Giacobbe A., D'Urso L., Falchi M., Venneri M.A., Muto G., De Maria R., Bonci D. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011, 30:4231-4242.
8. Bandi N., Zbinden S., Gugger M., Arnold M., Kocher V., Hasan L., Kappeler A., Brunner T., Vassella E. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009, 69:5553-5559.
9. Sun C.Y., She X.M., Qin Y., Chu Z.B., Chen L., Ai L.S., Zhang L., Hu Y. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013, 34:426-435.
10. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13944-13949.
11. Aqeilan R.I., Calin G.A., Croce C.M. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010, 17:215-220.
12. Roush S., Slack F.J. The let-7 family of microRNAs. Trends Cell Biol. 2008, 18:505-516.
13. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 micrornas in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756.
14. Trang P., Medina P.P., Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Homer R., Brown D., Bader A.G., Weidhaas J.B., Slack F.J. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010, 29:1580-1587.
15. Esquela-Kerscher A., Trang P., Wiggins J.F., Patrawala L., Cheng A., Ford L., Weidhaas J.B., Brown D., Bader A.G., Slack F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7:759-764.
16. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3903-3908.
17. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., Weidhaas J.B., Bader A.G., Slack F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19:1116-1122.
18. Qian P., Zuo Z., Wu Z., Meng X., Li G., Zhang W., Tan S., Pandey V., Yao Y., Wang P., Zhao L., Wang J., Wu Q., Song E., Lobie P.E., Yin Z., Zhu T. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 2011, 71:6463-6474.
19. Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., Liu C.G., Giannakakis A., Alexiou P., Hasegawa K., Johnstone C.N., Megraw M.S., Adams S., Lassus H., Huang J., Kaur S., Liang S., Sethupathy P., Leminen A., Simossis V.A., Sandaltzopoulos R., Naomoto Y., Katsaros D., Gimotty P.A., DeMichele A., Huang Q., Butzow R., Rustgi A.K., Weber B.L., Birrer M.J., Hatzigeorgiou A.G., Croce C.M., Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7004-7009.
20. Liu C., Kelnar K., Vlassov A.V., Brown D., Wang J., Tang D.G. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 2012, 72:3393-3404.
21. Brueckner B., Stresemann C., Kuner R., Mund C., Musch T., Meister M., Sultmann H., Lyko F. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007, 67:1419-1423.
22. Lu L., Katsaros D., de la Longrais I.A., Sochirca O., Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007, 67:10117-10122.
23. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., Zeng Y.X., Shao J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
24. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
25. Sampson V.B., Rong N.H., Han J., Yang Q., Aris V., Soteropoulos P., Petrelli N.J., Dunn S.P., Krueger L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007, 67:9762-9770.
26. Lee Y.S., Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007, 21:1025-1030.
27. Johnson C.D., Esquela-Kerscher A., Stefani G., Byrom M., Kelnar K., Ovcharenko D., Wilson M., Wang X., Shelton J., Shingara J., Chin L., Brown D., Slack F.J. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007, 67:7713-7722.
28. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A.L., Linsley P.S., Chen C., Lowe S.W., Cleary M.A., Hannon G.J. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
29. Hsu S.D., Chu C.H., Tsou A.P., Chen S.J., Chen H.C., Hsu P.W., Wong Y.H., Chen Y.H., Chen G.H., Huang H.D. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2008, 36:D165-D169.
30. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., Knyazev P., Diebold J., Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
31. Tanaka N., Toyooka S., Soh J., Kubo T., Yamamoto H., Maki Y., Muraoka T., Shien K., Furukawa M., Ueno T., Asano H., Tsukuda K., Aoe K., Miyoshi S. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer 2012, 76:32-38.
32. Lujambio A., Calin G.A., Villanueva A., Ropero S., Sanchez-Cespedes M., Blanco D., Montuenga L.M., Rossi S., Nicoloso M.S., Faller W.J., Gallagher W.M., Eccles S.A., Croce C.M., Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13556-13561.
33. Toyota M., Suzuki H., Sasaki Y., Maruyama R., Imai K., Shinomura Y., Tokino T. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008, 68:4123-4132.
34. Corney D.C., Hwang C.I., Matoso A., Vogt M., Flesken-Nikitin A., Godwin A.K., Kamat A.A., Sood A.K., Ellenson L.H., Hermeking H., Nikitin A.Y. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 2010, 16:1119-1128.
35. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 2007, 7:819-822.
36. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
37. Kim N.H., Kim H.S., Li X.Y., Lee I., Choi H.S., Kang S.E., Cha S.Y., Ryu J.K., Yoon D., Fearon E.R., Rowe R.G., Lee S., Maher C.A., Weiss S.J., Yook J.I. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 2011, 195:417-433.
38. Rokavec M., Oner M.G., Li H., Jackstadt R., Jiang L., Lodygin D., Kaller M., Horst D., Ziegler P.K., Schwitalla S., Slotta-Huspenina J., Bader F.G., Greten F.R., Hermeking H. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 2014, 124:1853-1867.
39. Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Patrawala L., Brown D., Bader A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
40. Craig V.J., Tzankov A., Flori M., Schmid C.A., Bader A.G., Muller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012, 26:2421-2424.
41. Pramanik D., Campbell N.R., Karikari C., Chivukula R., Kent O.A., Mendell J.T., Maitra A. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 2011, 10:1470-1480.
42. Bouchie A. First microRNA mimic enters clinic. Nat. Biotechnol. 2013, 31:577.
43. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
44. Hill L., Browne G., Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int. J. Cancer 2013, 132:745-754.
45. Schickel R., Park S.M., Murmann A.E., Peter M.E. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol. Cell 2010, 38:908-915.
46. Iliopoulos D., Lindahl-Allen M., Polytarchou C., Hirsch H.A., Tsichlis P.N., Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell 2010, 39:761-772.
47. Pecot C.V., Rupaimoole R., Yang D., Akbani R., Ivan C., Lu C., Wu S., Han H.D., Shah M.Y., Rodriguez-Aguayo C., Bottsford-Miller J., Liu Y., Kim S.B., Unruh A., Gonzalez-Villasana V., Huang L., Zand B., Moreno-Smith M., Mangala L.S., Taylor M., Dalton H.J., Sehgal V., Wen Y., Kang Y., Baggerly K.A., Lee J.S., Ram P.T., Ravoori M.K., Kundra V., Zhang X., Ali-Fehmi R., Gonzalez-Angulo A.M., Massion P.P., Calin G.A., Lopez-Berestein G., Zhang W., Sood A.K. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 2013, 4:2427.
48. Tejero R., Navarro A., Campayo M., Vinolas N., Marrades R.M., Cordeiro A., Ruiz-Martinez M., Santasusagna S., Molins L., Ramirez J., Monzo M. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS ONE 2014, 9:e101899.
49. Yu J., Ohuchida K., Mizumoto K., Sato N., Kayashima T., Fujita H., Nakata K., Tanaka M. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol. Cancer 2010, 9:169.
50. Pichler M., Ress A.L., Winter E., Stiegelbauer V., Karbiener M., Schwarzenbacher D., Scheideler M., Ivan C., Jahn S.W., Kiesslich T., Gerger A., Bauernhofer T., Calin G.A., Hoefler G. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br. J. Cancer 2014, 110:1614-1621.
51. Song F., Yang D., Liu B., Guo Y., Zheng H., Li L., Wang T., Yu J., Zhao Y., Niu R., Liang H., Winkler H., Zhang W., Hao X., Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin. Cancer Res. 2014, 20:878-889.
52. Wiklund E.D., Bramsen J.B., Hulf T., Dyrskjot L., Ramanathan R., Hansen T.B., Villadsen S.B., Gao S., Ostenfeld M.S., Borre M., Peter M.E., Orntoft T.F., Kjems J., Clark S.J. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 2011, 128:1327-1334.
53. Hu X., Macdonald D.M., Huettner P.C., Feng Z., El Naqa I.M., Schwarz J.K., Mutch D.G., Grigsby P.W., Powell S.N., Wang X. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol. Oncol. 2009, 114:457-464.
54. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
55. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
56. Woods K., Thomson J.M., Hammond S.M. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem. 2007, 282:2130-2134.
57. Sylvestre Y., De Guire V., Querido E., Mukhopadhyay U.K., Bourdeau V., Major F., Ferbeyre G., Chartrand P. An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem. 2007, 282:2135-2143.
58. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., Henderson J.M., Kutok J.L., Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008, 9:405-414.
59. Hong L., Lai M., Chen M., Xie C., Liao R., Kang Y.J., Xiao C., Hu W.Y., Han J., Sun P. The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence. Cancer Res. 2010, 70:8547-8557.
60. Inomata M., Tagawa H., Guo Y.M., Kameoka Y., Takahashi N., Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009, 113:396-402.
61. Dews M., Homayouni A., Yu D., Murphy D., Sevignani C., Wentzel E., Furth E.E., Lee W.M., Enders G.H., Mendell J.T., Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 2006, 38:1060-1065.
62. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., Tomida S., Yatabe Y., Kawahara K., Sekido Y., Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65:9628-9632.
63. Yu J., Ohuchida K., Mizumoto K., Fujita H., Nakata K., Tanaka M. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol. Ther. 2010, 10:748-757.
64. Chow T.F., Mankaruos M., Scorilas A., Youssef Y., Girgis A., Mossad S., Metias S., Rofael Y., Honey R.J., Stewart R., Pace K.T., Yousef G.M. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J. Urol. 2010, 183:743-751.
65. Matsubara H., Takeuchi T., Nishikawa E., Yanagisawa K., Hayashita Y., Ebi H., Yamada H., Suzuki M., Nagino M., Nimura Y., Osada H., Takahashi T. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007, 26:6099-6105.
66. Fulci V., Chiaretti S., Goldoni M., Azzalin G., Carucci N., Tavolaro S., Castellano L., Magrelli A., Citarella F., Messina M., Maggio R., Peragine N., Santangelo S., Mauro F.R., Landgraf P., Tuschl T., Weir D.B., Chien M., Russo J.J., Ju J., Sheridan R., Sander C., Zavolan M., Guarini A., Foa R., Macino G. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109:4944-4951.
67. Lawrie C.H., Soneji S., Marafioti T., Cooper C.D., Palazzo S., Paterson J.C., Cattan H., Enver T., Mager R., Boultwood J., Wainscoat J.S., Hatton C.S. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer 2007, 121:1156-1161.
68. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
69. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
70. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., Jacob S.T., Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99:671-678.
71. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
72. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
73. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2257-2261.
74. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., Croce C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24:4677-4684.
75. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., Taccioli C., Volinia S., Liu C.G., Alder H., Calin G.A., Menard S., Croce C.M. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67:8699-8707.
76. Zhang Z., Li Z., Gao C., Chen P., Chen J., Liu W., Xiao S., Lu H. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab. Investig. 2008, 88:1358-1366.
77. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
78. Hatley M.E., Patrick D.M., Garcia M.R., Richardson J.A., Bassel-Duby R., van Rooij E., Olson E.N. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010, 18:282-293.
79. Papagiannakopoulos T., Shapiro A., Kosik K.S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008, 68:8164-8172.
80. Zhu S., Si M.L., Wu H., Mo Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 2007, 282:14328-14336.
81. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
82. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28:5369-5380.
83. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
84. Fujita S., Ito T., Mizutani T., Minoguchi S., Yamamichi N., Sakurai K., Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol. 2008, 378:492-504.
85. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
86. Leone E., Morelli E., Di Martino M.T., Amodio N., Foresta U., Gulla A., Rossi M., Neri A., Giordano A., Munshi N.C., Anderson K.C., Tagliaferri P., Tassone P. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin. Cancer Res. 2013, 19:2096-2106.
87. Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., Croce C.M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7024-7029.
88. Jamieson N.B., Morran D.C., Morton J.P., Ali A., Dickson E.J., Carter C.R., Sansom O.J., Evans T.R., McKay C.J., Oien K.A. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2012, 18:534-545.
89. Kong W., He L., Richards E.J., Challa S., Xu C.X., Permuth-Wey J., Lancaster J.M., Coppola D., Sellers T.A., Djeu J.Y., Cheng J.Q. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014, 33:679-689.
90. Costinean S., Sandhu S.K., Pedersen I.M., Tili E., Trotta R., Perrotti D., Ciarlariello D., Neviani P., Harb J., Kauffman L.R., Shidham A., Croce C.M. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009, 114:1374-1382.
91. Gironella M., Seux M., Xie M.J., Cano C., Tomasini R., Gommeaux J., Garcia S., Nowak J., Yeung M.L., Jeang K.T., Chaix A., Fazli L., Motoo Y., Wang Q., Rocchi P., Russo A., Gleave M., Dagorn J.C., Iovanna J.L., Carrier A., Pebusque M.J., Dusetti N.J. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16170-16175.
92. Kong W., Yang H., He L., Zhao J.J., Coppola D., Dalton W.S., Cheng J.Q. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28:6773-6784.
93. Johansson J., Berg T., Kurzejamska E., Pang M.F., Tabor V., Jansson M., Roswall P., Pietras K., Sund M., Religa P., Fuxe J. MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013, 32:5614-5624.
94. Neilsen P.M., Noll J.E., Mattiske S., Bracken C.P., Gregory P.A., Schulz R.B., Lim S.P., Kumar R., Suetani R.J., Goodall G.J., Callen D.F. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2013, 32:2992-3000.
95. Bakirtzi K., Hatziapostolou M., Karagiannides I., Polytarchou C., Jaeger S., Iliopoulos D., Pothoulakis C. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 2011, 141:1749-1761. (e1741).
96. Jiang S., Zhang H.W., Lu M.H., He X.H., Li Y., Gu H., Liu M.F., Wang E.D. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70:3119-3127.
97. Kong W., He L., Coppola M., Guo J., Esposito N.N., Coppola D., Cheng J.Q. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 2010, 285:17869-17879.
98. Rai D., Kim S.W., McKeller M.R., Dahia P.L., Aguiar R.C. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3111-3116.
99. Zhang P., Bill K., Liu J., Young E., Peng T., Bolshakov S., Hoffman A., Song Y., Demicco E.G., Terrada D.L., Creighton C.J., Anderson M.L., Lazar A.J., Calin G.G., Pollock R.E., Lev D. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res. 2012, 72:1751-1762.
100. Tili E., Michaille J.J., Croce C.M. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol. Rev. 2013, 253:167-184.
101. Babar I.A., Cheng C.J., Booth C.J., Liang X., Weidhaas J.B., Saltzman W.M., Slack F.J. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1695-E1704.
102. Zhang M., Zhou X., Wang B., Yung B.C., Lee L.J., Ghoshal K., Lee R.J. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J. Control. Release 2013, 168:251-261.
103. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8:187-198.
104. Pezzolesi M.G., Platzer P., Waite K.A., Eng C. Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am. J. Hum. Genet. 2008, 82:1141-1149.
105. Garofalo M., Di Leva G., Romano G., Nuovo G., Suh S.S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., Gasparini P., Gonelli A., Costinean S., Acunzo M., Condorelli G., Croce C.M. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509.
106. Wang F., Li T., Zhang B., Li H., Wu Q., Yang L., Nie Y., Wu K., Shi Y., Fan D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem. Biophys. Res. Commun. 2013, 434:688-694.
107. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., Wenham R.M., Coppola D., Kruk P.A., Nicosia S.V., Cheng J.Q. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68:425-433.
108. Gong C., Yao Y., Wang Y., Liu B., Wu W., Chen J., Su F., Yao H., Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 2011, 286:19127-19137.
109. Ren Y., Zhou X., Mei M., Yuan X.B., Han L., Wang G.X., Jia Z.F., Xu P., Pu P.Y., Kang C.S. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer 2010, 10:27.
110. Qian X., Ren Y., Shi Z., Long L., Pu P., Sheng J., Yuan X., Kang C. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol. Pharm. 2012, 9:2636-2645.
111. Li Y., Zhu X., Gu J., Dong D., Yao J., Lin C., Huang K., Fei J. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 2010, 101:948-954.
112. Sicard F., Gayral M., Lulka H., Buscail L., Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol. Ther. 2013, 21:986-994.
113. Valeri N., Gasparini P., Braconi C., Paone A., Lovat F., Fabbri M., Sumani K.M., Alder H., Amadori D., Patel T., Nuovo G.J., Fishel R., Croce C.M. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21098-21103.
114. Zang Y.S., Zhong Y.F., Fang Z., Li B., An J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther. 2012, 19:773-778.
115. Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., Cho Y.J. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro. Oncol. 2011, 13:165-175.
116. Vinall R.L., Ripoll A.Z., Wang S., Pan C.X., deVere White R.W. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int. J. Cancer 2012, 130:2526-2538.
117. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009, 4:e6816.
118. Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70:1501-1512.
119. Kastl L., Brown I., Schofield A.C. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res. Treat. 2012, 131:445-454.
120. Catuogno S., Cerchia L., Romano G., Pognonec P., Condorelli G., de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 2013, 32:341-351.
121. Zhao J., Kelnar K., Bader A.G. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS ONE 2014, 9:e89105.
122. Shimizu S., Takehara T., Hikita H., Kodama T., Miyagi T., Hosui A., Tatsumi T., Ishida H., Noda T., Nagano H., Doki Y., Mori M., Hayashi N. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol. 2010, 52:698-704.
123. Sugimura K., Miyata H., Tanaka K., Hamano R., Takahashi T., Kurokawa Y., Yamasaki M., Nakajima K., Takiguchi S., Mori M., Doki Y. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin. Cancer Res. 2012, 18:5144-5153.
124. Pouliot L.M., Chen Y.C., Bai J., Guha R., Martin S.E., Gottesman M.M., Hall M.D. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 2012, 72:5945-5955.
125. Yu P.N., Yan M.D., Lai H.C., Huang R.L., Chou Y.C., Lin W.C., Yeh L.T., Lin Y.W. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int. J. Cancer 2014, 134:542-551.
126. Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., Zhuang S.M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009, 69:1135-1142.
127. Crawford M., Batte K., Yu L., Wu X., Nuovo G.J., Marsh C.B., Otterson G.A., Nana-Sinkam S.P. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 2009, 388:483-489.
128. Braconi C., Valeri N., Gasparini P., Huang N., Taccioli C., Nuovo G., Suzuki T., Croce C.M., Patel T. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 2010, 16:957-966.
129. Li H., Hui L., Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:269-277.
130. Zhu W., Shan X., Wang T., Shu Y., Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer 2010, 127:2520-2529.
131. Nishida N., Mimori K., Fabbri M., Yokobori T., Sudo T., Tanaka F., Shibata K., Ishii H., Doki Y., Mori M. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin. Cancer Res. 2011, 17:2725-2733.
132. Min W., Wang B., Li J., Han J., Zhao Y., Su W., Dai Z., Wang X., Ma Q. The expression and significance of five types of miRNAs in breast cancer. Med. Sci. Monit. Basic Res. 2014, 20:97-104.
133. Hashiguchi Y., Nishida N., Mimori K., Sudo T., Tanaka F., Shibata K., Ishii H., Mochizuki H., Hase K., Doki Y., Mori M. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int. J. Oncol. 2012, 40:1477-1482.
134. Jiang L., Huang Q., Zhang S., Zhang Q., Chang J., Qiu X., Wang E. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010, 10:318.
135. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., Menard S., Croce C.M., Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69:2195-2200.
136. Ye X.M., Zhu H.Y., Bai W.D., Wang T., Wang L., Chen Y., Yang A.G., Jia L.T. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer 2014, 14:134.
137. Dalby K.N., Tekedereli I., Lopez-Berestein G., Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010, 6:322-329.
138. Zou Z., Wu L., Ding H., Wang Y., Zhang Y., Chen X., Zhang C.Y., Zhang Q., Zen K. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J. Biol. Chem. 2012, 287:4148-4156.
139. Hurteau G.J., Carlson J.A., Spivack S.D., Brock G.J. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67:7972-7976.
140. Kopp F., Oak P.S., Wagner E., Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE 2012, 7:e50469.
141. Cittelly D.M., Dimitrova I., Howe E.N., Cochrane D.R., Jean A., Spoelstra N.S., Post M.D., Lu X., Broaddus R.R., Spillman M.A., Richer J.K. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol. Cancer Ther. 2012, 11:2556-2565.
142. Ceppi P., Mudduluru G., Kumarswamy R., Rapa I., Scagliotti G.V., Papotti M., Allgayer H. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res. 2010, 8:1207-1216.
143. Bryant J.L., Britson J., Balko J.M., Willian M., Timmons R., Frolov A., Black E.P. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br. J. Cancer 2012, 106:148-156.
144. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
145. Chang C.J., Hsu C.C., Chang C.H., Tsai L.L., Chang Y.C., Lu S.W., Yu C.H., Huang H.S., Wang J.J., Tsai C.H., Chou M.Y., Yu C.C., Hu F.W. Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol. Rep. 2011, 26:1003-1010.
146. Ward A., Balwierz A., Zhang J.D., Kublbeck M., Pawitan Y., Hielscher T., Wiemann S., Sahin O. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013, 32:1173-1182.
147. Bockhorn J., Dalton R., Nwachukwu C., Huang S., Prat A., Yee K., Chang Y.F., Huo D., Wen Y., Swanson K.E., Qiu T., Lu J., Park S.Y., Dolan M.E., Perou C.M., Olopade O.I., Clarke M.F., Greene G.L., Liu H. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat. Commun. 2013, 4:1393.
148. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
149. Gallach S., Calabuig-Farinas S., Jantus-Lewintre E., Camps C. MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res. Int. 2014, 2014:878450.
150. Liu L.Z., Li C., Chen Q., Jing Y., Carpenter R., Jiang Y., Kung H.F., Lai L., Jiang B.H. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS ONE 2011, 6:e19139.
151. Cascio S., D'Andrea A., Ferla R., Surmacz E., Gulotta E., Amodeo V., Bazan V., Gebbia N., Russo A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J. Cell. Physiol. 2010, 224:242-249.
152. Shi Z., Chen Q., Li C., Wang L., Qian X., Jiang C., Liu X., Wang X., Li H., Kang C., Jiang T., Liu L.Z., You Y., Liu N., Jiang B.H. MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro. Oncol. 2014, 16:1341-1353.
153. Qian X., Yu J., Yin Y., He J., Wang L., Li Q., Zhang L.Q., Li C.Y., Shi Z.M., Xu Q., Li W., Lai L.H., Liu L.Z., Jiang B.H. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 2013, 12:1385-1394.
154. Fang L., Deng Z., Shatseva T., Yang J., Peng C., Du W.W., Yee A.J., Ang L.C., He C., Shan S.W., Yang B.B. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2011, 30:806-821.
155. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13:714-726.
156. Zhu H., Wu H., Liu X., Evans B.R., Medina D.J., Liu C.G., Yang J.M. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 2008, 76:582-588.
157. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., Pogribny I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7:2152-2159.
158. Feng D.D., Zhang H., Zhang P., Zheng Y.S., Zhang X.J., Han B.W., Luo X.Q., Xu L., Zhou H., Qu L.H., Chen Y.Q. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J. Cell. Mol. Med. 2011, 15:2164-2175.
159. Yang T., Zheng Z.M., Li X.N., Li Z.F., Wang Y., Geng Y.F., Bai L., Zhang X.B. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp. Biol. Med. 2013, 238:1024-1032.
160. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., Wagar N., Yoon Y., Cho H.T., Scala S., Shim H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 2010, 79:817-824.
161. Xu K., Liang X., Shen K., Cui D., Zheng Y., Xu J., Fan Z., Qiu Y., Li Q., Ni L., Liu J. miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem. J. 2012, 446:291-300.
162. Jiao X., Zhao L., Ma M., Bai X., He M., Yan Y., Wang Y., Chen Q., Zhao X., Zhou M., Cui Z., Zheng Z., Wang E., Wei M. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res. Treat. 2013, 139:717-730.
163. Ma M.T., He M., Wang Y., Jiao X.Y., Zhao L., Bai X.F., Yu Z.J., Wu H.Z., Sun M.L., Song Z.G., Wei M.J. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett. 2013, 339:107-115.
164. Aliabadi H.M., Landry B., Sun C., Tang T., Uludag H. Supramolecular assemblies in functional siRNA delivery: where do we stand?. Biomaterials 2012, 33:2546-2569.
165. Bader A.G., Brown D., Stoudemire J., Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011, 18:1121-1126.
166. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
167. Daka A., Peer D. RNAi-based nanomedicine for targeted personalized therapy. Adv. Drug Deliv. Rev. 2012, 1508-1521.
168. Chen Y., Gao D.Y., Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv. Drug Deliv. Rev. 2014, (Epub ahead of print).
169. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., Jacks T., Anderson D.G. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2012, 12:39-50.
170. Howard K.A. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Deliv. Rev. 2009, 61:710-720.
171. Varkouhi A.K., Scholte M., Storm G., Haisma H.J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151:220-228.
172. Molinaro R., Wolfram J., Federico C., Cilurzo F., Di Marzio L., Ventura C.A., Carafa M., Celia C., Fresta M. Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opin. Drug Deliv. 2013, 10:1653-1668.
173. Hobel S., Aigner A. Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2013, 5:484-501.
174. Grayson A.C., Doody A.M., Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 2006, 23:1868-1876.
175. Hwang D.W., Son S., Jang J., Youn H., Lee S., Lee D., Lee Y.S., Jeong J.M., Kim W.J., Lee D.S. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32:4968-4975.
176. Shcharbin D., Shakhbazau A., Bryszewska M. Poly(amidoamine) dendrimer complexes as a platform for gene delivery. Expert Opin. Drug Deliv. 2013, 10:1687-1698.
177. Eichman J.D., Bielinska A.U., Kukowska-Latallo J.F., Baker J.R. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm. Sci. Technol. Today 2000, 3:232-245.
178. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J.R. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4897-4902.
179. Zhou J., Wu J., Hafdi N., Behr J.P., Erbacher P., Peng L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem. Commun. (Camb.) 2006, 2362-2364.
180. Kang H., DeLong R., Fisher M.H., Juliano R.L. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 2005, 22:2099-2106.
181. Gray W.D., Wu R.J., Yin X., Zhou J., Davis M.E., Luo Y. Dendrimeric bowties featuring hemispheric-selective decoration of ligands for microRNA-based therapy. Biomacromolecules 2013, 14:101-109.
182. Buschmann M.D., Merzouki A., Lavertu M., Thibault M., Jean M., Darras V. Chitosans for delivery of nucleic acids. Adv. Drug Deliv. Rev. 2013, 65:1234-1270.
183. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 2006, 115:216-225.
184. Ragelle H., Riva R., Vandermeulen G., Naeye B., Pourcelle V., Le Duff C.S., D'Haese C., Nysten B., Braeckmans K., De Smedt S.C., Jerome C., Preat V. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. J. Control. Release 2014, 176:54-63.
185. Agarwal S., Zhang Y., Maji S., Greiner A. PDMAEMA based gene delivery materials. Mater. Today 2012, 15:388-393.
186. van de Wetering P., Cherng J.-Y., Talsma H., Hennink W.E. Relation between transfection efficiency and cytotoxicity of poly (2-(dimethylamino) ethyl methacrylate)/plasmid complexes. J. Control. Release 1997, 49:59-69.
187. Jones R.A., Poniris M.H., Wilson M.R. pDMAEMA is internalised by endocytosis but does not physically disrupt endosomes. J. Control. Release 2004, 96:379-391.
188. Convertine A.J., Benoit D.S., Duvall C.L., Hoffman A.S., Stayton P.S. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J. Control. Release 2009, 133:221-229.
189. Nelson C.E., Kintzing J.R., Hanna A., Shannon J.M., Gupta M.K., Duvall C.L. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano 2013, 7:8870-8880.
190. Mittal A., Chitkara D., Behrman S.W., Mahato R.I. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 2014, 35:7077-7087.
191. Qian X., Long L., Shi Z., Liu C., Qiu M., Sheng J., Pu P., Yuan X., Ren Y., Kang C. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials 2014, 35:2322-2335.
192. Deng X., Cao M., Zhang J., Hu K., Yin Z., Zhou Z., Xiao X., Yang Y., Sheng W., Wu Y., Zeng Y. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 2014, 35:4333-4344.
193. Liu Q., Li R.T., Qian H.Q., Wei J., Xie L., Shen J., Yang M., Qian X.P., Yu L.X., Jiang X.Q., Liu B.R. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 2013, 34:7191-7203.
194. Choi K.Y., Silvestre O.F., Huang X., Min K.H., Howard G.P., Hida N., Jin A.J., Carvajal N., Lee S.W., Hong J.I., Chen X. A versatile RNA-interference nanoplatform for systemic delivery of RNAs. ACS Nano 2014, 8:4559-4570.
195. Zhi F., Dong H., Jia X., Guo W., Lu H., Yang Y., Ju H., Zhang X., Hu Y. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS ONE 2013, 8:e60034.
196. Yang H.W., Huang C.Y., Lin C.W., Liu H.L., Huang C.W., Liao S.S., Chen P.Y., Lu Y.J., Wei K.C., Ma C.C. Gadolinium-functionalized nanographene oxide for combined drug and microRNA delivery and magnetic resonance imaging. Biomaterials 2014, 35:6534-6542.
197. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 2003, 5:834-839.
198. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., Lovat F., Fadda P., Mao C., Nuovo G.J., Zanesi N., Crawford M., Ozer G.H., Wernicke D., Alder H., Caligiuri M.A., Nana-Sinkam P., Perrotti D., Croce C.M. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2110-E2116.
199. Ballarin-Gonzalez B., Howard K.A. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv. Drug Deliv. Rev. 2012, 64:1717-1729.
200. Akhtar S., Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 2007, 59:164-182.
201. Lee M.J., Ye A.S., Gardino A.K., Heijink A.M., Sorger P.K., MacBeath G., Yaffe M.B. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780-794.